| Original language | English |
|---|---|
| Pages (from-to) | 1721-1723 |
| Number of pages | 3 |
| Journal | JACC: Cardiovascular Imaging |
| Volume | 11 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published or Issued - Nov 2018 |
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JACC: Cardiovascular Imaging, Vol. 11, No. 11, 11.2018, p. 1721-1723.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease
T2 - Frequency-Domain Optical Coherence Tomography Analysis
AU - Takata, Kohei
AU - Kataoka, Yu
AU - Andrews, Jordan
AU - Puri, Rishi
AU - Hammadah, Muhammad
AU - Duggal, Bhanu
AU - Kapadia, Samir R.
AU - Tuzcu, E. Murat
AU - Nissen, Steven E.
AU - Nicholls, Stephen J.
N1 - Funding Information: Please note: Dr. Nissen has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi-Aventis, Resverlogix, and Eli Lilly; and is a consultant or advisor for many pharmaceutical companies but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr. Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda; has received consulting fees from AstraZeneca, Abbott, Atheronova, Esperion, Amgen, Novartis, Omthera, CSL Behring, Boehringer Ingelheim, Pfizer, Merck Schering-Plough, Takeda, Roche, NovoNordisk, LipoScience, and Anthera; and has received research support from the National Health and Medical Research Council of Australia, Amgen, Esperion, The Medicines Company, Sanofi-Regeneron, Anthera, AstraZeneca, Cerenis, Eli Lilly, InfraReDx, Roche, Resverlogix, Novartis, Amgen, and LipoScience. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2018/11
Y1 - 2018/11
UR - http://www.scopus.com/inward/record.url?scp=85056409406&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2018.02.017
DO - 10.1016/j.jcmg.2018.02.017
M3 - Letter
C2 - 29680344
AN - SCOPUS:85056409406
SN - 1936-878X
VL - 11
SP - 1721
EP - 1723
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 11
ER -